India's First International News Journal

India's First International News Journal

Wednesday, September, 28, 2022

Press Release

Senores Pharmaceuticals, Inc. announces the launch of Mexiletine Hydrochloride Capsules USP, 150 mg, 200 mg and 250 mg with one of the top generic pharmaceutical companies in the U.S. market
S

ATLANTA, Jan. 27, 2022 /PRNewswire/ — Senores Pharmaceuticals, Inc. announced the launch of Mexiletine Hydrochloride Capsules USP, 150 mg, 200 mg and 250 mg, a therapeutic equivalent version of MEXITIL (Mexiletine Hydrochloride) with one of the top 5 generic pharmaceutical companies in the U.S. market.

Mexiletine Hydrochloride Capsules, USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

“We are thrilled to announce the commercial launch of Mexiletine Hydrochloride Capsules in the U.S. market,” stated Dhananjay Barot, Director, Senores Pharmaceuticals, Inc. “Our unwavering commitment towards the pharmaceutical industry makes us a prominent supplier for this product,” stated Swapnil Shah, Managing Director, Senores Group.

About Senores Pharmaceuticals, Inc. 

Senores Pharmaceuticals, based in Atlanta, Georgia is one of the fastest-growing pharmaceutical companies in the U.S. market. Currently, the company has more than 15 products commercially launched or filed with the USFDA.

For more information about Senores Pharmaceuticals, Inc., please visit www.senorespharma.com Senores Pharmaceuticals, Inc. Atlanta,Georgia

Logo: https://mma.prnewswire.com/media/1735313/Senores_Pharma_Logo.jpg

Disclaimer: This Press Release has not been vetted or endorsed by The Eastern Herald's editorial staff.

The stories shaping the world

Partner Agency

PR Newswire
PR Newswire
News and Press Releases curated/syndicated via PR Newswire feed. PR Newswire is a distributor of press releases headquartered in New York City.

Trending

You may consider